Futura Medical Share Discussion Threads

[petroc] 12/12/2022 17:27

Stock bashing has become very common in the digital world and often occurs on online trading platforms. Sophisticated technology makes it easy for bashers to remain anonymous. As such, it can be difficult to track, identify, and stop bashers in their tracks.

As the internet makes participation in the stock market more accessible to more people, new investors emerging in the market are especially vulnerable to the tactics of stock bashers, and many investor boards exist to attempt to track perpetrators.

Though notoriously difficult to track, some bashers have been identified and prosecuted. From time to time, confessional essays about the tactics of bashers emerge online, although these essays are typically also either anonymous or pseudonymous. Many investors speculate this type of behavior tends to follow certain patterns, including a tendency for bashers to only bash stocks which are generally trending upwards and showing potential.

Having said that, financial regulators constantly monitor the markets for what they call bad actors or stock bashers. According to the Financial Industry Regulatory Authority (FINRA), investors may find it difficult to get information about these securities and any tidbits they may find can lead them to act even if it's misinformation. That's why FINRA warned investment firms and broker-dealers to put controls in place that would raise red flags on any suspicious activity

[broomrigg] 12/12/2022 17:17

Excuse me for interrupting the enthralling banter on here but I have some BREAKING NEWS!!......

FUM 10 days of continuous gains! That's 10 BLUE days in a row! Well done FUM keep it up.

:-)

[lbo] 12/12/2022 16:47

Devices are subject to weaker standards than drugs because they are regulated under a different law.

Ninety-nine percent of devices never have to provide clinical data, thanks in part to the 2002 Medical Devices User Fee Act, which requires the FDA to use the least burdensome route

For the few devices subject to a scientific review, the quality standards are flimsy. Randomized controlled trials, the gold standard, are infrequent. Most studies are unblinded, and thus prone to bias. The FDA settles for loosely defined reasonable assurance that a device is safe and effective, versus its higher standard of substantial evidence for drugs, which require studies with comparison groups that didnt receive the same treatment. Thus, data that would never be sufficient to support the approval of a drug can result in the approval of a device used to treat the same condition, potentially diverting patients from effective drugs to less-effective devices.



whether or not placebo use is ethical depends partly on whether patients are being deceived and whether there is a known better treatment. A clinician who doesn’t deceive a patient, and who provides a placebo for something for which there is no known treatment, such as irritable bowel syndrome, might be ethically OK, says Jeremy Howick, of the Department of Primary Health Care Sciences, at the University of Oxford, and lead author of the Plos One study. But there is no evidence that this company is enhancing care. What they have been doing is completely unethical’

[lbo] 12/12/2022 13:58

Rumours!? All public knowledge as its been touted by all the Futura paid for research and rampers all over the internet! The rampers are pumping on no news and will dump if any news is released! As they say. If the news is in the market then its in the price! All public knowledge!!!'Commercial execution is key'˜The next steps are EU launches (due to start during H123), FDA marketing clearance (potentially by end Q123)'we have limited visibility on the potential timing and terms, given various structures and options could be considered. Importantly, current cash resources should be sufficient to reach beyond the anticipated US regulatory decision by end Q123, and to secure a US deal, assuming a positive regulatory outcome catalyses discussions’‘The first wave of launches is anticipated during H123, which could potentially include the UK. The next wave will likely include the rest of the key markets of France, Germany, Italy, and Spain, with the third wave being the distributor-led smaller geographies. A contract manufacturer is in place for commercial production and first orders have already been received from Cooper’

[j777j] 12/12/2022 13:06

Rumours...



FDA approval


Major US commercial partner announcement


Europe and UK product launches




All due soon and any of the above will send the share price sharply higher




See you all soon in the 90's


Hugs and kisses

Mwah Mwah mwah

[petroc] 12/12/2022 12:20

Hahahaha! LiarBO just said to Mike - 'How many times have you repeatedly posted the same misleading post.' What an absolute buffoon! How many times has LiarBO posted his copy/pasted misleading posts? Well, at a rate of say, 15 a day, over 5 years, I'd say the answer is roughly 30,000. What an absolute tool the stock basher is!